- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Standardized template for clinical reporting of PSMA PET/CT scans ; day:15 ; month:8 ; year:2024 ; pages:1-7
European journal of nuclear medicine and molecular imaging ; (15.8.2024), 1-7
- Urheber
-
Esfahani, Shadi A.
Morris, Michael J.
Sartor, Oliver
Frydenberg, Mark
Fanti, Stefano
Calais, Jeremie
Vapiwala, Neha
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-024-06857-w
- URN
-
urn:nbn:de:101:1-2411022104176.061029368396
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Esfahani, Shadi A.
- Morris, Michael J.
- Sartor, Oliver
- Frydenberg, Mark
- Fanti, Stefano
- Calais, Jeremie
- Vapiwala, Neha
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens](/assets/placeholder/searchResultMediaUnknown.png)
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on \(^18}\)F-DCFPyL PET/CT Imaging
Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
Metabolic tumour volume from PSMA PET/CT scans of prostate cancer patients during chemotherapy - do different software solutions deliver comparable results?
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
68Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on \(^18}\)F-DCFPyL PET/CT Imaging
Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
Metabolic tumour volume from PSMA PET/CT scans of prostate cancer patients during chemotherapy - do different software solutions deliver comparable results?
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
68Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on \(^18}\)F-DCFPyL PET/CT Imaging
Meta-analysis of 18 F-PSMA-1007 PET/CT, 18 F-FDG PET/CT, and 68Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
Metabolic tumour volume from PSMA PET/CT scans of prostate cancer patients during chemotherapy - do different software solutions deliver comparable results?
Pitfalls in PSMA imaging: [18F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy